{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:09:13Z","timestamp":1778872153057,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32CA163177-12"],"award-info":[{"award-number":["5T32CA163177-12"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is central to treating patients with epithelioid peritoneal mesothelioma (EPM). Male sex is a negative prognostic factor in mesothelioma, but the reasons for this remain unclear. We evaluated the impact of sex and age, as a proxy for menopause status, on treatment patterns and survival for EPM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Adults with unicavitary EPM were identified in the National Cancer Database (NCDB) (2006\u20132020). Predictors of CRS\/HIPEC receipt were evaluated using logistic regression. Among patients who underwent CRS\/HIPEC, variables impacting overall survival (OS) were evaluated using Cox regression. Patients were stratified by age (\u2264 40\u00a0years and \u2265 60\u00a0years) into younger male, older male, premenopausal female, and postmenopausal female patients for subgroup analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 1868 patients meeting inclusion criteria, 28.1% (\n                      <jats:italic>n<\/jats:italic>\n                      = 526) received CRS\/HIPEC; of those, 286 (54.4%) were male. Male sex (odds ratio, OR 1.054,\n                      <jats:italic>p\u2009<\/jats:italic>\n                      =\u20090.015), younger age (OR 0.996,\n                      <jats:italic>p\u2009<\/jats:italic>\n                      &lt;\u20090.001), and treatment at an academic center (OR 1.253,\n                      <jats:italic>p\u2009<\/jats:italic>\n                      &lt;\u20090.001) were independently associated with receiving CRS\/HIPEC. Males had worse OS than females after CRS\/HIPEC on multivariable regression (hazard ratio, HR 1.647,\n                      <jats:italic>p\u2009<\/jats:italic>\n                      =\u20090.003). Upon age-stratification of patients who underwent CRS\/HIPEC, premenopausal females had significantly improved OS compared with younger male, older male, and postmenopausal female patients on Kaplan\u2013Meier analysis (all\n                      <jats:italic>p\u2009<\/jats:italic>\n                      &lt;\u20090.05). Female sex significantly predicted survival in younger (HR 0.267,\n                      <jats:italic>p\u2009<\/jats:italic>\n                      =\u20090.012) but not older patients (HR 0.676,\n                      <jats:italic>p\u2009<\/jats:italic>\n                      =\u20090.061).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Premenopausal women with EPM undergoing CRS\/HIPEC had significantly improved OS compared with both males and postmenopausal females, suggesting a hormonal influence on outcomes. Future studies to elucidate the biological mechanisms underlying this sex-based disparity are necessary.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19455-x","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:44:01Z","timestamp":1773326641000},"page":"5304-5314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hormonal Status May Contribute to Sex-Based Survival Differences in Epithelioid Peritoneal Mesothelioma"],"prefix":"10.1245","volume":"33","author":[{"given":"Kaelyn C.","family":"Cummins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Sears","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elio R.","family":"Bitar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengli","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Tsung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha M.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"6","key":"19455_CR1","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1093\/annonc\/mdr477","volume":"23","author":"C Cao","year":"2012","unstructured":"Cao C, Yan TD, Deraco M, et al. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol. 2012;23(6):1494\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdr477.","journal-title":"Ann Oncol."},{"issue":"2","key":"19455_CR2","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41379-020-00688-4","volume":"34","author":"DB Chapel","year":"2021","unstructured":"Chapel DB, Schulte JJ, Absenger G, et al. Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. Mod Pathol. 2021;34(2):380\u201395. https:\/\/doi.org\/10.1038\/s41379-020-00688-4.","journal-title":"Mod Pathol."},{"issue":"7","key":"19455_CR3","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1245\/s10434-018-6499-1","volume":"25","author":"V Verma","year":"2018","unstructured":"Verma V, Sleightholm RL, Rusthoven CG, et al. Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival. Ann Surg Oncol. 2018;25(7):2018\u201326. https:\/\/doi.org\/10.1245\/s10434-018-6499-1.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"19455_CR4","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1245\/s10434-019-08139-4","volume":"27","author":"JC Leinwand","year":"2020","unstructured":"Leinwand JC, Taub RN, Chabot JA, Kluger MD. Two-stage cytoreductive surgery and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: predictors of overall survival in an intention-to-treat series. Ann Surg Oncol. 2020;27(7):2539\u201347. https:\/\/doi.org\/10.1245\/s10434-019-08139-4.","journal-title":"Ann Surg Oncol."},{"key":"19455_CR5","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17358-x","author":"LM Brown","year":"2025","unstructured":"Brown LM, Wilkins SG, Bansal VV, et al. Consensus guideline for the management of peritoneal mesothelioma. Ann Surg Oncol. 2025. https:\/\/doi.org\/10.1245\/s10434-025-17358-x.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"19455_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41568-024-00680-z","volume":"24","author":"T Xiao","year":"2024","unstructured":"Xiao T, Lee J, Gauntner TD, Velegraki M, Lathia JD, Li Z. Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications. Nat Rev Cancer. 2024;24(5):338\u201355. https:\/\/doi.org\/10.1038\/s41568-024-00680-z.","journal-title":"Nat Rev Cancer."},{"issue":"11","key":"19455_CR7","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1158\/0008-5472.CAN-08-4523","volume":"69","author":"G Pinton","year":"2009","unstructured":"Pinton G, Brunelli E, Murer B, et al. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res. 2009;69(11):4598\u2013604. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4523.","journal-title":"Cancer Res."},{"key":"19455_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12957-015-0624-4","volume":"13","author":"Y Huang","year":"2015","unstructured":"Huang Y, Alzahrani NA, Liauw W, Morris DL. Effects of sex hormones on survival of peritoneal mesothelioma. World J Surg Oncol. 2015;13:210. https:\/\/doi.org\/10.1186\/s12957-015-0624-4.","journal-title":"World J Surg Oncol."},{"issue":"1","key":"19455_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/XCS.0000000000001214","volume":"240","author":"EB Habermann","year":"2025","unstructured":"Habermann EB, Day CN, Palis BE, et al. American College of Surgeons Cancer Program annual report from 2021 participant user file. J Am Coll Surg. 2025;240(1):95\u2013110. https:\/\/doi.org\/10.1097\/XCS.0000000000001214.","journal-title":"J Am Coll Surg."},{"issue":"13","key":"19455_CR10","doi-asserted-by":"publisher","first-page":"8549","DOI":"10.1245\/s10434-024-16142-7","volume":"31","author":"A Khomiak","year":"2024","unstructured":"Khomiak A, Ghaffar S, Rodriguez Franco S, et al. Survival outcomes of cytoreductive surgery with hipec in gastric adenocarcinoma: a national cancer database study. Ann Surg Oncol. 2024;31(13):8549\u201359. https:\/\/doi.org\/10.1245\/s10434-024-16142-7.","journal-title":"Ann Surg Oncol."},{"key":"19455_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2025.116235","volume":"242","author":"Z Pelc","year":"2025","unstructured":"Pelc Z, Sedlak K, Endo Y, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal metastasis\u2014Joint analysis of European GASTRODATA and American national cancer database. Am J Surg. 2025;242:116235. https:\/\/doi.org\/10.1016\/j.amjsurg.2025.116235.","journal-title":"Am J Surg."},{"issue":"4","key":"19455_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250726","volume":"16","author":"NS Rozich","year":"2021","unstructured":"Rozich NS, Lewis SE, Chen S, et al. Women survive longer than men undergoing cytoreductive surgery and HIPEC for appendiceal cancer. PLoS One. 2021;16(4):e0250726. https:\/\/doi.org\/10.1371\/journal.pone.0250726.","journal-title":"PLoS One."},{"key":"19455_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jss.2019.01.039","volume":"238","author":"RM Byrne","year":"2019","unstructured":"Byrne RM, Gilbert EW, Dewey EN, et al. Who undergoes cytoreductive surgery and perioperative intraperitoneal chemotherapy for appendiceal cancer? An analysis of the National Cancer Database. J Surg Res. 2019;238:198\u2013206. https:\/\/doi.org\/10.1016\/j.jss.2019.01.039.","journal-title":"J Surg Res."},{"key":"19455_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153990","author":"DC Freudenberger","year":"2023","unstructured":"Freudenberger DC, Vudatha V, Wolfe LG, et al. Race and ethnicity impacts overall survival of patients with appendiceal cancer who undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15153990.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"19455_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1245\/s10434-024-16446-8","volume":"32","author":"K Ramalingam","year":"2025","unstructured":"Ramalingam K, Ji L, O\u2019Leary MP, Lum SS, Caba Molina D. Medicaid expansion and overall survival of lower gastrointestinal cancer patients after cytoreductive surgery and heated intraperitoneal chemotherapy. Ann Surg Oncol. 2025;32(2):687\u201394. https:\/\/doi.org\/10.1245\/s10434-024-16446-8.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"19455_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1245\/s10434-024-16443-x","volume":"32","author":"M Stillman","year":"2025","unstructured":"Stillman M, Somasundar P, Espat NJ, Calvino AS, Kwon S. Negative impact of systemic therapy on survival in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade metastatic appendiceal adenocarcinoma. Ann Surg Oncol. 2025;32(1):221\u20139. https:\/\/doi.org\/10.1245\/s10434-024-16443-x.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"19455_CR17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jama.289.7.895","volume":"289","author":"LA Bastian","year":"2003","unstructured":"Bastian LA, Smith CM, Nanda K. Is this woman perimenopausal? JAMA. 2003;289(7):895\u2013902. https:\/\/doi.org\/10.1001\/jama.289.7.895.","journal-title":"JAMA."},{"key":"19455_CR18","unstructured":"Network NCC. NCCN clinical practice guidelines in oncology: mesothelioma: peritoneal. Updated October 3, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/meso_peritoneal.pdf"},{"key":"19455_CR19","doi-asserted-by":"publisher","first-page":"1480197","DOI":"10.3389\/fonc.2025.1480197","volume":"15","author":"X Wang","year":"2025","unstructured":"Wang X, Liu R, Wang C, Sun J, Yang D. Development and validation of a prognostic nomogram for patients with malignant peritoneal mesothelioma. Front Oncol. 2025;15:1480197. https:\/\/doi.org\/10.3389\/fonc.2025.1480197.","journal-title":"Front Oncol."},{"issue":"6","key":"19455_CR20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.jpedsurg.2024.02.002","volume":"59","author":"CP Nofi","year":"2024","unstructured":"Nofi CP, Roberts BK, Rich BS, Glick RD. Pediatric, Adolescent and young adult (AYA) peritoneal and pleural mesothelioma: a National Cancer Database Review. J Pediatr Surg. 2024;59(6):1113\u201320. https:\/\/doi.org\/10.1016\/j.jpedsurg.2024.02.002.","journal-title":"J Pediatr Surg."},{"issue":"8","key":"19455_CR21","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1245\/s10434-023-13528-x","volume":"30","author":"L Calthorpe","year":"2023","unstructured":"Calthorpe L, Romero-Hernandez F, Casey M, et al. National practice patterns in malignant peritoneal mesothelioma: updates in management and survival. Ann Surg Oncol. 2023;30(8):5119\u201329. https:\/\/doi.org\/10.1245\/s10434-023-13528-x.","journal-title":"Ann Surg Oncol."},{"issue":"12","key":"19455_CR22","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/bjs.5377","volume":"93","author":"TD Yan","year":"2006","unstructured":"Yan TD, Popa E, Brun EA, Cerruto CA, Sugarbaker PH. Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg. 2006;93(12):1536\u201342. https:\/\/doi.org\/10.1002\/bjs.5377.","journal-title":"Br J Surg."},{"issue":"4","key":"19455_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s12253-009-9170-0","volume":"15","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yao P, Akther J, et al. Differential expression of Ki-67 and sex steroid hormone receptors between genders in peritoneal mesothelioma. Pathol Oncol Res. 2009;15(4):671\u20138. https:\/\/doi.org\/10.1007\/s12253-009-9170-0.","journal-title":"Pathol Oncol Res."},{"issue":"4742","key":"19455_CR24","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1126\/science.3753802","volume":"231","author":"GL Greene","year":"1986","unstructured":"Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science. 1986;231(4742):1150\u20134. https:\/\/doi.org\/10.1126\/science.3753802.","journal-title":"Science."},{"key":"19455_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18081713","author":"LH Hsu","year":"2017","unstructured":"Hsu LH, Chu NM, Kao SH. Estrogen, estrogen receptor and lung cancer. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18081713.","journal-title":"Int J Mol Sci."},{"key":"19455_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26104611","author":"B Smolarz","year":"2025","unstructured":"Smolarz B, Biernacka K, Lukasiewicz H, et al. Ovarian cancer-epidemiology, classification, pathogenesis, treatment, and estrogen receptors\u2019 molecular backgrounds. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26104611.","journal-title":"Int J Mol Sci."},{"issue":"5","key":"19455_CR27","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1007\/s11033-020-05414-6","volume":"47","author":"JW Maingi","year":"2020","unstructured":"Maingi JW, Tang S, Liu S, Ngenya W, Bao E. Targeting estrogen receptors in colorectal cancer. Mol Biol Rep. 2020;47(5):4087\u201391. https:\/\/doi.org\/10.1007\/s11033-020-05414-6.","journal-title":"Mol Biol Rep."},{"key":"19455_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076834","author":"L Clusan","year":"2023","unstructured":"Clusan L, Ferriere F, Flouriot G, Pakdel F. A basic review on estrogen receptor signaling pathways in breast cancer. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24076834.","journal-title":"Int J Mol Sci."},{"issue":"6","key":"19455_CR29","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00432-013-1408-2","volume":"139","author":"K Pillai","year":"2013","unstructured":"Pillai K, Pourgholami MH, Chua TC, Morris DL. Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 2013;139(6):987\u201394. https:\/\/doi.org\/10.1007\/s00432-013-1408-2.","journal-title":"J Cancer Res Clin Oncol."},{"issue":"2","key":"19455_CR30","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/jso.27882","volume":"131","author":"C Drigotas","year":"2025","unstructured":"Drigotas C, Loftus AW, Ammori JB, Rothermel LD, Hoehn RS. Perfusion Strategies for cytoreductive surgery with heated intraperitoneal chemotherapy for malignant peritoneal mesothelioma. J Surg Oncol. 2025;131(2):310\u20135. https:\/\/doi.org\/10.1002\/jso.27882.","journal-title":"J Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19455-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:27:26Z","timestamp":1778869646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19455-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["19455"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19455-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}